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Chapter 1 
General introduction 
 
1-1 Role of intestinal microbiota in host health 
Large numbers of bacteria, as much as 10
12
 CFU of bacteria in 1g of digesta, are 
present in the human intestine. They constitute a complex microbial community that 
interacts with host intestinal tissues to secrete protective molecules such as IgA and 
defensin peptides (Masuda et al., 2011). Indigenous microbiota have the potential to 
inhibit colonization of pathogens (Stecher and Hardt, 2008). Indeed, traveller’s diarrhea 
is a typical result of imbalanced intestinal microbiota (Mathewson et al., 1985). 
In addition to host defense, intestinal microbiota can attenuate host nutrition with the 
modification of hormone secretions (Cani et al., 2009). Since intestinal tissues secrete 
several peptide hormones that influence movement of the digestive tract as well as the 
appetite of the host (Naslund et al., 1999), the connection between intestinal microbiota 
and energy homeostasis of the host is increasingly recognized. Some studies have 
indicated that altered intestinal microbiota are associated with obesity. For example, the 
number of Firmicutes was increased, whereas the number of Bacteroidetes was reduced, 
in obese mice and humans compared with lean individuals (Ley et al., 2005; Turnbaugh 
et al., 2006; Ley et al., 2006; Furet et al., 2010). Children becoming overweight by 7 
years of age had lower levels of bifidobacteria and higher levels of Staphylococcus 
aureus during the first year of life than infants maintaining a healthy weight 
(Kalliomäki et al., 2008). 
In this context, a certain modification of intestinal microbiota can deteriorate or 
improve human health. The existence of a better composition of intestinal microbiota 
has been supposed to be true. Restoration or remodification of intestinal microbiota is 
therefore believed to be effective to prevent or even cure the deteriorated status of host 
health. 
 
1-2 Probiotic for enteric disorders  
A bacterium that provides specific health benefits when consumed as a food 
component or supplement has been referred to a probiotic. Typical probiotics are those 
belonging to genera Lactobacillus and Bifidobacterium. Probiotics have the potential to 
modify the composition of intestinal microbiota (Ohashi et al., 2001). Accordingly, it is 
widely recognized that probiotics can restore deteriorated microbiota. Lactobacillus 
rhamnosus GG can cure traveller’s diarrhea (Oksanen et al., 1990; Sazawal et al., 2006). 
In other cases, probiotics can prevent infection of some enteric pathogens (Table 1-1). 
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The probiotic bacterium L. rhamnosus GG has been applied to rotavirus-infected 
children to cure or prevent diarrhea by stimulation of specific IgA responses to the 
rotavirus (Majamaa et al., 1995). 
 On the other hand, non-pathogenic and non-life-threatening enteric disorders such as 
severe constipation can be cured or prevented by probiotics (Table 1-2). Enterococcus 
faecalis EC12 enhances chloride secretion from the intestine through induction of 
Na
+
-K
+
-2Cl
-
 co-transporter 1 (NKCC1) in enterocytes to increase the water content of 
digesta, which improves the constipation (Inoue et al., 2007). 
In addition to enteric disorders, probiotics attract attention for their preventive effect 
on allergies (Table 1-3). 
 
1-3 Relation between intestinal microbiota and obesity 
Obesity is defined as the excess accumulation of visceral adipose tissue (WHO, 2011) 
which is induced by a lack of exercise and improper dietary habits. Visceral fat 
accumulation is a major risk factor for the development of diabetes, hyperlipidemia, 
hypertension, and arteriosclerosis. Intestinal microbiota have a role in the host’s 
metabolic homeostasis (Cani et al., 2009). According to Cani et al., an altered 
composition of the intestinal microbiota is associated with type 2 diabetes mellitus and 
obesity. Since obesity is inevitably associated with low-grade inflammation, a bacterial 
compound, which is an inducer of inflammation, might act as a triggering factor in the 
development of obesity. Cani suggested that this bacterial compound might be 
lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria, 
because the mice lacking the major LPS co-receptor CD14 were resistant to 
high-fat-diet-induced inflammation and metabolic diseases. Additionally, in 
high-fat-diet-fed mice, dietary modulation of intestinal microbiota to increase 
bifidobacteria reduced endotoxemia as well as reducing inflammation development. 
This finding suggests that intestinal microbiota contribute to the pathophysiological 
regulation of endotoxemia (Cani et al., 2007). 
On the other hand, short-chain fatty acids have been proposed to bind to specific 
G-protein-coupled receptors (GPR43), which contributes to an increase in adipocyte 
differentiation and inhibits lipolysis in the adipose tissue. So short-chain fatty acids 
(SCFA) produced by probiotic bacteria could act as metabolic regulators of energy 
uptake in adipose tissue (Kimura et al., 2013). 
 
1-4 Aim of this study 
 As discussed above, the potential of probiotics as health promoters is now widely 
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accepted, evidenced by the huge variety of commercial products with a successful sales 
record. Probiotics are composed mainly of lactic acid bacteria; as they are common in 
traditional fermented foods, the safety of the products is quite obvious. This situation 
may have helped to increase the market for probiotics. 
However, the mode of its action has not been clarified so far in many cases. This is 
because probiotics show effects on disorders not only directly but also indirectly. 
Interaction with the host’s natural immune system is defined as direct action of 
probiotics. Therefore, involvement of a Toll-like receptor (TLR) in the health-beneficial 
effect of probiotics has been discussed frequently. Th1 and Th2 cytokine balance was 
once discussed (Shida et al., 1998), and an induction of T-regulatory cells was the focus 
of recent probiotic studies (Torii et al., 2007). Secretion of beneficial products such as 
SCFA or growth promotion of other indigenous health-beneficial bacteria is defined as 
indirect action of probiotics (Ohashi et al., 2001). 
The aims of this study were to investigate (1) the effect of a tablet containing probiotic 
lactobacilli and medicinal herbs on the fecal microbiota in humans, (2) the effect of a 
probiotic, L. gasseri NT, on lipid metabolism in normal mice, (3) in an obese model, 
and to make clear the targeted organs of affection. 
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Table 1-1 Improvement of pathogen-induced diseases by probiotics in human or mice 
model 
Probiotic 
Dose 
Human/
mice 
Pathogens Results References 
species 
L. rhamnosus GG Fermented milk and 
powder (1010-1011)/day 
Human RV Period of diarrhea ↓ Isolauri et al., 1991 
          
L. rhamnosus GG Fermented milk and 
powder (1010-1011)/day 
Human RV Period of diarrhea ↓ Kaila et al., 1992 
     
B. bifidum 1.9×10
8 CFU/g Human RV Morbidity of diarrhea ↓ Saavedra et al., 1994 
S. thermophilus 1.4×10
7 CFU/g   
L. rhamnosus GG 1×10
10 CFU/day Human RV Period of diarrhea ↓ Isolauri et al., 1994 
L. rhamnosus GG 1.9×10
8 CFU/g   RV Period of diarrhea ↓, Majamaa et al., 1995 
        IgA ↑   
L. reuteri 10
7 or 1010 CFU/g Human RV Period of diarrhea ↓ Shornikova et al., 1997 
B. breve YIT4064 5×10
10 CFU/day   RV Infection of RV ↓ Araki et al., 1999 
L. acidophilus 10
9 viable/day Human RV Period of diarrhea ↓ Lee et al., 2001 
B. infantis 10
9 viable/day  
L. rhamnosus 10
10 CFU/day Human RV Period of diarrhea ↓ Rosenfeldt et al., 2002 
L. reuteri 10
10 CFU/day   
C. butyricum 10
8 CFU/day Mice EHEC Survival rate↑ Takahashi et al., 2004  
   Shigera toxin ↓  
B. longum BB536 NR GF mice EHEC Survival rate↑ Namba et al., 2003  
        EHEC ↓   
RV: rotavirus; EHEC: enterohemorrhagic E. coli 
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Table 1-2 Effects of probiotics on constipation in humans 
Probiotic 
Dose Results References 
species 
B. longum BB536 Fermented milk Improvement  Yaeshima et al., 1997 
 (2×10
9/day) defecation frequency↑  
L. casei Shirota Beverage (6.5×10
9/day) Improvement  Koebnick et al., 2003 
      
B. lactis DN-173 Fermented milk Improvement  Yang et al., 2008 
  (1.25×1010/day)     
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Table 1-3 Preventive effects on allergies by probiotics 
Probiotic 
Dose Type of allergy Results References 
species 
L. paracasei Fermented milk Perennial allergic 
rhinitis 
Improved quality of life Wang et al., 2004 
 (2×10
9 CFU/day) 
 
 
B. longum BB536 Powder Cedar pollen Reduced ocular symptom 
scores 
Xiao et al., 2007 
  (5×1010 CFU/day)     
L. acidophilus L-55 Yogurt Cedar pollen Reduced ocular symptom 
scores, IgE↓ 
Kimura et al., 2012 
    
L. casei Shirota Fermented milk Seasonal allergic 
rhinitis 
IgE↓, IgG↑ Ivory et al., 2008 
          
L. rhamnosus GG Powder in capsule Atopic disease Morbidity of atopy ↓ Kalliomäki et al., 2001 
 
(1×1010 CFU/day) 
   
L. fermentum 
VRI-033 
1×109 CFU/day 
Atopic disease Improvement of SCORAD 
Weston et al., 2005 
B. breve M-16V Powder Atopic disease Bifidobacterium↑ Taniuchi et al., 2005 
      Improvement of SCORAD   
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Chapter 2 
Effect of a tablet containing probiotic bacteria and stomachic herbs on human fecal 
microbiota 
 
2-1 Introduction 
Probiotic bacteria, namely lactobacilli and bifidobacteria, are now well recognized for 
their health promoting effects (Macfarlane et al., 1999). Administration of probiotics is 
often realized orally by a single dose, although sometimes they are dosed with 
medicinal plant materials. Lactic acid bacteria react with gut epithelial tissues to affect 
the mucosal immunity through the stimulation of toll-like receptors (TLRs). Lactic acid 
bacteria affect the host physiology through chloride secretion from the gut, to increase 
water contents of the digesta (Inoue et al., 2007) , and modification of the sympathetic 
and parasympathetic nervous systems, to reduce blood pressure and blood sugar levels 
(Tanida et al., 2005). Probiotics also strongly affect the host's indigenous intestinal 
microbiota (Ohashi et al., 2001, Ohashi et al., 2006). Indeed, they promote different 
colonic fermentation patterns (Ohashi et al., 2004). Probiotics, more precisely 
fermented milk, may affect the gastric emptying, reducing the digesta transit (Ohashi et 
al., 1997). Digesta kinetics have strong influences on the digestion, therefore the 
administration of probiotics can modulate the amount of material flowing into the large 
intestine. The availability of probiotics should modify the composition of the microbiota. 
Medicinal plants such as swertia, cinnamon, and fennel, have long been administered to 
patients with digestive troubles. They engage with the host's digestive physiological 
systems, though the mechanisms are undefined. The introduction of these medicinal 
plants into probiotic therapies may modulate the effects of probiotics. In this chapter, 
the effect of a tablet containing both probiotic and medicinal herbs on the fecal 
microbiota is shown in human volunteers. 
 
2-2 Materials and Methods 
Six healthy volunteers (4 men and 2 women, aged from 24 to 55 years old, average 
age : 36) were recruited from Nitto Pharmaceutical Industries, Ltd. to test a tablet 
containing probiotics and medicinal plants. Experiments were conducted in accordance 
with the Declaration of Helsinki. All subjects were informed of the details of the present 
study and gave their consent to participate. No restrictions of food choice were imposed 
on the subjects throughout the study, except prohibition of ingestion of fermented milk, 
fermented soybeans and pickles the day before the sampling. The tablet is a probiotic 
product, the Guard (Kowa Shinyaku Co. Ltd. Japan) and contains Bacillus natto 
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NT(Bacillus natto)(10
8 
cfu/9 tablets), Lactobacillus acidophilus NT (Lactomin) (10
9 
cfu/9 tablets), dimethylpolysiloxane, powdered swertia herb, powdered cinnamon bark, 
powdered fennel, methyl methionine sulfonium chloride, precipitated calcium carbonate, 
magnesium carbonate (Table 2-1). The 6 healthy subjects took 3 tablets, 3 times a day 
after meals for 10 days. Stool samples were collected before and after the administration 
period. An additional sampling was made 7 days after the end of administration. Fresh 
feces were transferred into sterile plastic tubes (50 ml) containing 30 ml of ethanol to 
maintain an ethanol concentration in excess of 70%. Samples of feces were kept at 5°C 
until the analyses, which were performed within three months of collection. After 
homogenization, a portion of the suspension was centrifuged (6,700×g, for 10 min, 4°C) 
and the pellets were collected. Approximately 0.2 g of pellets were washed twice with 
1×phosphate-buffered saline (PBS). Bacterial DNA was extracted from the pellets using 
ISOFECAL for Beads Beating kit (NIPPON GENE Co. Ltd) and FastPrep FP120 
(BIO101 Co. Ltd). All individual samples of bacterial 16S rRNA gene were subjected to 
temperature gradient gel electrophoresis (TGGE) analysis as described elsewhere (Inoue 
et al., 2003, Muyzer et al., 1993). The gel image was taken by a densitometer (GS-800; 
Bio-Rad, California, USA). The profiles were analyzed using a software package for 
imaging and analyzing electrophoresis gels (Quantity one, Bio-Rad, California, USA), 
and cluster analysis of the TGGE band profiles was performed using hierarchical 
clustering analysis with Euclidean square distances using the Microsoft Excel macro 
program developed by S. Aoki (Gunma University, Maebashi, Japan; program available 
at http://aoki2.si.gunma-u.ac.jp/lecture/stats-by-excel/vba/html/clustan.htm). A 
corresponding dendrogram was constructed with Ward linkages. In this study, very 
weakly stained bands with an optical density (OD) of <0.1 as determined by the 
software were ignored, because on occasion such bands cannot be identified 
automatically by the software and this could result in artifacts in the analysis. The 
density of the bands, as determined by the software, was not used in the analysis. If a 
lane had a band at a certain position, an assignment of “1”was made; if there was no 
band at the same position, an assignment of “0”was made. A mixture of 16S rRNA gene 
of known bacteria (Inoue et al., 2003) was applied to the TGGE gels as standard 
markers. B.natto NT and L. acidophilus NT were also used as standards. Twenty one 
bands on the TGGE gel were excised and put into 20μl of sterile water. The excised gel 
was left in water overnight at 4℃ to elute the DNA (Ohashi et al., 2004). These bands 
(indicated in Fig. 2-3) were selected because their densities had changed remarkably 
between before and after the probiotic administration. After the extraction step was 
performed, a portion of eluted DNA solution was amplified with primers 968F, which 
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do not contain the 40 bases GC clump and univ-R. The PCR conditions were principally 
the same as described elsewhere (Inoue et al., 2003) except for the cycle number: 30 
cycles. The size and amount of the PCR products were confirmed by analyzing all 
samples by 1.5% agarose gel (wt/vol) electrophoresis and ethidium bromide staining. 
The obtained bands were purified using Wizard SV Gel and PCR Clean-UP System 
(Promega, Tokyo, Japan). Purified products were sequenced after TA-cloning, as 
described elsewhere (Ohashi et al., 2004). Briefly, PCR amplicons were ligated into 
pGEM-T vector (Bio-Rad, Tokyo, Japan) and Escherichia coli JM109 was transformed. 
Clones harboring amplified DNA were selected by blue-white screening, and 8 white 
clones were randomly selected from each plate (one plate for each TGGE band). Colony 
PCR using SP6 and T7 primers was performed to check the size of inserted DNA with 
r-Taq polymerase. The following thermal cycle was applied: 94°C for 3 min of initial 
denaturation followed by 25 cycles of 94°C for 30 sec, 48°C for 30 sec, and 72°C for 50 
sec, with a final elongation at 72°C for 3 min. Restriction fragment length 
polymorphism (RFLP) analyses of PCR products were performed with Hae Ⅲ(Toyobo, 
Tokyo, Japan), HhaⅠ(Toyobo), and RsaⅠ(Toyobo) according to the manufacturer’s 
instructions to group the obtained E.coli clones. Although several clone groups were 
recognized for each excised TGGE band, the most abundant clone group was selected 
and the insert of one randomly selected clone from the clone group was sequenced. 
Sequencing was performed at Shimadzu Genomic Research, Co. Ltd. (Kyoto, Japan). 
Sequences were compared via the BLAST program at NCBI 
(http://www.ncbi.nlm.nih.gov/blast) with those registered in databases (such as 
DDBJ/EMBL/ GenBank) to suggest possible taxonomic names. The relative abundance 
of bifidobacterial 16S rRNA gene in fecal samples was quantified with the Light Cycler 
system (Roche Diagnostics, Tokyo, Japan).The FastStart DNA Master SYBR Green I 
was used for PCR. The reaction mixture (20μl) contained 3 mM MgCl2, 2μl of the 
10×Mastermix, 20 ng of fecal DNA, and 0.5μM of each primer. For quantification of 
total bifidobacterial 16S rRNA gene, the primers g-Bifid-F 
(5’-CTCCTGGAAACGGGTGG-3’) and g-Bifid-R 
(5’-GGTGTTCTTCCCGATATCTACA-3’) were used (Matsuki et al., 1998). The 
thermal program consisted of initial denaturation at 95°C for 30 sec followed by 40 
cycles of 95°C for 4 sec and 62°C for 25 sec. Dilutions of the genomic DNA from 
Bifidobacterium longum JCM7050 of known amount of viable count were used to 
construct calibration curves. These calibration curves were applied to the calculation of 
the total count of Bifidobacterium in fecal samples. 
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2-3 Results 
The bacterial species, which may typically contribute to the change in the diversity of 
the intestinal microbiota, appearing as TGGE bands were detected. The detected bands 
are shown in Fig. 2-1.  
The band profiles differing between before and after intake as evidenced by cluster 
analysis are shown in Fig. 2-2. According to the dendrogram created from the TGGE 
band profiles, profiles from D-after and E-after constructed one cluster. Others tended to 
construct one cluster for each subject such as A- before with A-after. According to the 
clustering analysis (Fig. 2-2), Subjects A, B, C and F formed one group, and subject D 
clustered with subject E. This result indicates that the intestinal microbiota of subjects D 
and E were relatively similar to each other and that the composition of microbiota was 
modified in a similar manner by the mixture of probiotics and herbs.  
There was a band with increased density which was commonly shared by 4 subjects 
(A, D, E, F) below the bottom markers (Fig. 2-1). On the other hand, there were no 
remarkable changes in the bands which existed at the same position in lane L. 
acidophilus NT and B. natto NT for each subject. Twenty-one TGGE bands, indicated in 
Fig. 2-3, whose density changed remarkably were identified. Table 2-2 shows the results 
of sequence analyses of these TGGE bands. Bifidobacterium-like sequences were 
determined for band 1 to band 10; Haemophilus-like sequences were determined for 
band 11 and band 12; a butyrate-producing bacterium-like sequence was determined for 
band 13; an Acidaminococcus-like sequence was determined for band 14; 
Ruminococcus-like sequences were determined for band 15 and band 16; a 
butyrate-producing bacterium-like sequence was determined for band 17; a Clostridium 
colinum-like sequence was determined for band 18; a Ruminococcus-like sequence and 
a Clostridium orbiscidens-like sequence were determined for band 19; and 
Megamonas-like sequences were determined for band 20 and band 21. 
In the case of subject A, the density of the bands identified as Bifidobacterium 
increased after the probiotic tablet administration. In the case of subject B, the density 
of the bands identified as Haemophilus and butyrate-producing bacterium decreased 
and the density of the band identified as Acidaminococcus increased after the 
administration. In the case of subject C, the density of the bands identified as 
Ruminococcus and Bifidobacterium decreased after the administration. In the case of 
subject D, the density of the bands identified as butyrate-producing bacterium and 
Bifidobacterium increased after the administration. In the case of subject E, the density 
of the bands identified as Bifidobacterium increased after the administration. In the case 
of subject F, the density of the bands identified as Bifidobacterium, Megamonas and 
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Ruminococcus or Clostridium orbiscidens increased and the density of the band 
identified as Clostridium colinum decreased after the administration. 
 
2-4 Discussion 
The estimated total cell numbers of bifidobacteria are listed in Table 2-3. The number 
of bifidobacteria increased after administration of the probiotic tablet in four subjects (A, 
D, E and F), decreased a little in one subject (C), and decreased in one subject (B).The 
TGGE results showed common and individual changes of intestinal microflora among 
the six subjects. In four cases out of six, the density of the bands identified with 
Bifidobacterium increased after administration of the probiotic tablet. This was 
confirmed by real-time PCR. The results indicate that intake of the probiotic tablet 
affected colonic environment and had a bifidogenic effect on at least four of the six 
subjects with different magnitudes. Individual differences in response to the tablet 
administration may reflect individual differences in composition of intestinal microflora. 
A similar observation was reported by Ohashi et al (Ohashi et al., 2004) about the cecal 
fermentation pattern.  
In the present experiment, for example, subjects D and E, both had relatively similar 
intestinal microflora as evidenced by the cluster analysis of their TGGE profiles. 
Bifidobacteria increased by some 30 to 40% after administration of the probiotic tablet. 
Subject F showed a similar level of increase (45%) in the size of the bifidobacterial 
population. Among the four positively responding subjects in terms of bifidobacteria, 
subject A showed a notable increase of 380%. Interestingly, subject A showed the 
smallest bifidobacterial population before the administration of the tablets. At the 
moment we do not know of any specific component of intestinal microflora other than 
bifidobacteria which would result in an increase in bifidobacteria.  
Another particular modification in intestinal microbiota was the stimulation of 
lactate-utilizing bacteria such as Acidaminococcus, butyrate-producing bacterium, and 
Megamonas. These bacteria produced butyric acid or propionic acid from lactic acid. An 
increase in bifidobacteria may help higher lactate production, but it is important to 
convert lactate into short-chain fatty acids by lactate-utilizers, because butyrate and 
propionate have particular importance for the host health (Kameue et al., 2006, 
Kishimoto et al., 2006). 
This type of human study needs a certain level of subject numbers due to the 
tremendous heterogenesity of human intestinal microbiota. Indeed, each person has 
his(her) own composition of microbiota. However, even with the limited number of 
subjects, there was no general tendency of modification of intestinal bacteria. In this 
12 
experiment, since only 6 subjects were available, the sample number was too small to 
draw a definitive conclusion. Individual differences in intestinal microbiota may be 
large enough to react with probiotics differently, because the interaction between 
indigenous intestinal bacteria and probiotic strains differ from one individual to another 
(Ohashi et al., 2004, Ohashi et al., 2006). In the case of rodent models, the effects of 
intestinal modifiers such as dietary prebiotics show a defined tendency as evidenced by 
clearly separated clusters (i.e., administer and non-adminiser) (Maekawa et al., 2005). 
This is because the rodent model has a relatively well defined and simplified intestinal 
microbiota (Yanabe et al., 2001). Such a condition cannot be achieved in human 
experiments. Therefore, substantial numbers of subjects are needed to draw a general 
conclusion about the effects of probiotics or prebiotics in human cases. This experiment 
was indeed a preliminary one. However, there were some changes about band profiles in 
all subjects and particularly stimulation of bifidobacteria was detected in four cases out 
of six. This can be considered as an indication of the potential of this mixture of 
probiotics and medicinal herb plants. 
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Fig. 2-1. Gel image of TGGE of bacterial 16S rRNA gene PCR product (rDNA) (developed by 
silver staining) 
A～F：Subjects; La：Lactobacillus acidophilus NT 16S rDNA; Bn：Bacillus natto NT 16S 
rDNA; M：marker; b：Before administration; a：After administration. The markers consisted of 
four bacterial 16S rDNA prepared in our laboratory. The four horizontal arrows along with the 
standard marker lanes indicate the 16S rDNA bands corresponding those of Ruminococcus 
hydrogenotrophicus (Accession number of GenBank：X95624, homology 91%), Clostridium sp. 
(AF157053, homology 85%), Escherichia coli (A14565, homology 100%), and Lactobacillus 
gasseri strain KC5a (AF243165, homology 97%) from top to bottom. 
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Fig. 2-2. Dendrogram obtained from hierarchical clustering of the TGGE band profiles. 
A～F：Subjects; b：Before administration; a：After administration 
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Fig. 2-3. Gel image of TGGE of bacterial 16S rRNA gene PCR product (developed by ethidium 
bromide staining). A～F：Subjects; M：marker; b：Before administration; a：After administration 
 
Table 2-2.Results of BLAST searches for partial sequences of bacterial 16S rRNA gene PCR product  
Subjects Band No． First match with known bacterium (Accession No.) Identity (%)
Bifidobacterium sp.  (AF306789) 100
Collinsella aerofaciens (AJ245920) 99
Bifidobacterium longum  (EF589112) 100
Lactobacillus sp  (AB158766) 96
11 Haemophilus parainfluenzae  (EU083530) 99
12 Haemophilus parainfluenzae  (EU083530) 99
13 Butyrate-producing bacterium  (AJ270469) 100
14 Acidaminococcaceae bacterium  (AB298734) 93
3 Bifidobacterium  sp (AF306789) 99
Bifidobacterium  sp (AF306789) 100
Bifidobacterium longum  (EF589112) 100
15 Ruminococcus sp  (EF036467) 100
16 Ruminococcus sp  (EF036467) 100
Bifidobacterium adolescentis  (AP009256) 98
Bifidobacterium longum  (EF589112) 99
Clostridium sp  (DQ100445) 91
Bifidobacterium adolescentis  (AP009256） 99
Collinsella aerofaciens  (AJ245920) 100
17 Butyrate-producing bacterium  (AJ27042) 94
7 Bifidobacterium adolescentis  (AY305304) 99
8 Bifidobacterium longum  (EF589112) 100
9 Bifidobacterium longum  (EF589112) 100
10 Bifidobacterium longum  (EF589112) 100
18 Clostridium colinum  (X76748) 92
19 Ruminococcus sp (EF036467) 99
Clostridium orbiscidens  (Y18187) 98
20 Megamonas sp  (EU346729) 99
21 Megamonas sp  (EU346729) 97
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Table 2-1. Ingredients of the tablet per nine tablets 
 
Ingredient dosage 
Bacillus natto 10 mg 
Lactomin 30 mg 
Dimethylpolysiloxane 84.6 mg 
Powdered Swertia Herb 30 mg 
Powdered Cinnamon Bark 30 mg 
Powdered Fennel 30 mg 
Methyl Methionine Sulfonium Chloride 30 mg 
Precipitated Calcium Carbonate 300 mg 
Magnesium Carbonate 300 mg 
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Table 2-3. The relative abundance (log10cell/g feces) of each operational taxonomic unit 
(OTU) related to bifidobacteria in the feces 
Subjects Before After Post 
A 
B 
C 
D 
E 
F 
8.71 
9.97 
9.70 
10.38 
10.43 
9.75 
9.28 
8.74 
9.28 
10.48 
10.57 
9.92 
10.08 
9.57 
9.85 
10.29 
10.03 
9.38 
Before：Before administration; After：After administration; Post：Post-administrat 
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Chapter 3 
Effect of lactic acid bacteria on lipid metabolism and fat synthesis in mice fed a high-fat 
diet 
 
3-1 Introduction 
Obesity is defined as the excess accumulation of visceral adipose tissue (WHO 2011) 
because of a lack of exercise and improper food habits. Visceral fat accumulation is a 
major risk factor for the development of several diseases, including diabetes, 
hyperlipidemia, hypertension and arteriosclerosis. Therefore, stimulation of lipolytic 
activity in adipose tissue or inhibition of fat synthesis is one way to prevent these 
serious diseases. For example, a dietary fiber, gum arabic, helps reduce body fat 
deposition by enhancing fat utilization in adipose tissues (Ushida et al., 2011). Higher 
lipolytic activity may be related to the higher expression level of beta 3 adrenaline 
receptor (ADRB3) in visceral adipose tissue. A decline in ADRB3 is, in fact, believed to 
contribute to the development of obesity (Fisler et al., 2008). On the other hand, the 
lipid composition of animal cells is controlled by SREBPs, transcription factors released 
from membranes by sterol-regulated proteolysis (Sakai et al., 1998). SREBPs are also 
known as a master regulator that participates in insulin resistance (Ide et al., 2004).  
Probiotics, namely, lactobacilli and bifidobacteria, are now well recognized for their 
health-promoting effects (Macfarlane et al., 1999). In many cases, lactic acid bacteria 
react with the mucosal immunity of the gut to exert a physiological effect (Ohashi et al., 
2009). For example, lactic acid bacteria stimulate chloride secretion from the gut to 
increase the water content of the digesta (Inoue et al., 2007) and adjust the sympathetic 
and parasympathetic nervous systems to reduce blood pressure and blood sugar levels 
(Tanida et al., 2005). The clearest effect was obtained in the improvement of 
hypercholesterolemia (Kondo et al., 2010). The anti-obesity effect of lactic acid bacteria 
has also been reported. For example, Usman and Hosono (Usman 1999) indicated the 
capability to remove cholesterol from a culture medium with Lactobacillus gasseri 
strains. Portugal et al. (Portugal et al., 2006) suggested that the effect of L. delbrueckii 
on cholesterol metabolism was through Apolipoprotein E (ApoE) which is a cholesterol 
transporter. These health-promoting effects may be related to the anti-obesity effects of 
lactic acid bacteria. Indeed, the anti-obesity effects of lactic acid bacteria have been 
reported. Kadooka et al. (Kadooka et al., 2010) indicated that administration of the 
probiotic bacterium L. gasseri in fermented milk reduced adiposity and body weight in 
obese adults, possibly by reducing lipid absorption and inflammatory status.  
In this chapter, we evaluated the effects of the administration of lactic acid bacteria 
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on lipid metabolism and fat synthesis in a mouse high-fat-diet model focusing on 
visceral fat. In addition, the use of an ex-vivo test to measure ADRB3-dependent fat 
mobilization is introduced to better determine the responsiveness of adipose tissue to 
adrenergic stimulation, since ADRB3 expression is an indirect indicator of fat 
mobilization. 
 
3-2 Materials and Methods 
Animal experiments 
Thirty 12-week-old female Balb/c mice were purchased from Japan SLC (Shizuoka, 
Japan). They were housed in five plastic cages (each containing six mice) in a room 
kept at 25±1°C with a 12-h light and dark cycle. The mice were divided into the 
following four groups: LaboMR (six mice fed a conventional crude and low fat diet, 
Labo MR Stock, Nihon Nosan Kogyo, Tokyo, Japan), 10%FD (six mice fed 10 kcal% 
fat diet, D12450B, Research Diets, Inc., New Brunswick, NJ, USA), 45%FD (nine mice 
fed 45 kcal% fat diet, D12451, Research Diets, Inc., New Brunswick, NJ, USA) and 
45%FD+Lg (nine mice fed 45 kcal% fat diet, D12451, Research Diets, Inc.) including 
Lactobacillus gasseri NT(10
9
 CFU/g). L. gasseri NT was originally isolated from 
human feces. The composition of each diet is shown in Table 3-1. The mice had free 
access to their diet and drinking water for 13 weeks. On the last day of feeding, the 
body weight and periovarian fat weight were measured. Periovarian fat, regarded as 
visceral adipose tissue, was removed through a midline incision. A portion of the 
periovarian fat was collected in RNAlater solution (Sigma, Japan) for mRNA analyses 
and in Hanks' Balanced Salt Solutions for the ex vivo test for lipolysis. A portion of the 
liver was removed and fixed in the RNAlater solution for mRNA analyses. Blood 
samples were collected from the inferior vena cava to measure the free fatty acid (FFA), 
triglyceride (TG) and insulin concentrations. 
The experiments were approved by the Animal Experiment Committee of Kyoto 
Prefectural University. 
 
Ex vivo test for lipolysis of visceral adipose tissue 
The collected fat tissues were cut into pieces of ca. 20 mg and cultured in 96-well 
plates with a basal medium. The basal medium was composed of DMEM/Ham’s F12 
(Nacalai Tesque, Kyoto, Japan) containing 10% (v/v) bovine fetal serum (Zhang et al., 
2000) and 1% (w/v) Pen-Strep Solution (10,000 units/mL penicillin and 10,000 ug/mL 
streptomycin in 0.85% NaCl) (Thermo Fisher Scientific, Kanagawa, Japan). After three 
hours of incubation, glycerol released into media was measured with the use of a 
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Glycerol Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA).  
 
Blood test 
Serum FFA and TG levels were determined using a NEFA C-test (Wako, Japan) and 
TG E-test (Wako, Japan), respectively. Serum insulin was measured using a Mouse 
Insulin Kit (Morinaga Institute of Biological Science, Yokohama, Japan).  
 
Determination of mRNA expression level 
Extraction of RNA from the periovarian adipose tissue and the liver and subsequent 
cDNA synthesis was carried out as reported elsewhere (Yoshikawa et al., 2009). The 
expression levels of each gene were evaluated by the real-time PCR approach using a 
LightCycler 480 Real-Time PCR System (Roche Applied Science, Tokyo, Japan). PCR 
was performed with a thermal cycle program with an initial denaturation at 95°C for 5 
min followed by 50 cycles of 95°C for 10 s and 60°C for 20 s. In this analysis, the 
β-actin gene was used as the housekeeping gene. The genes and the oligonucleotide 
primer sets together with TaqMan probes were as follows: beta actin (GeneBank 
accession number: NM007393), 5’-agagggaaatcgtgcgtgac-3’ (forward) and 
5’-caatagtgacctggccgt-3’ (reverse), Roche probe No.101; beta 3 adrenaline receptor 
(ADRB3; GeneBank accession number: NM013462), 5’-cagccagccctgttgaag-3’ 
(forward) and 5’-ccttcatagccatcaaacctg-3’ (reverse), Roche probe No.13; tumor necrosis 
factor alpha (TNF-α; GeneBank accession number: NM013693), 
5’-ttgtcttaacgctgatttggt-3’ (forward) and 5’-gggagcagaggttcagtgat-3’ (reverse), Roche 
probe No.64; monocyte chemoattractant protein 1 (MCP-1, CCL2; GeneBank accession 
number: NM011333), 5’-catccacgtgttggctca-3’ (forward) and 
5’-gatcatcttgctggtgaatgagt-3’ (reverse), Roche probe No.62; insulin receptor (INSR; 
GeneBank accession number: NM010568), 5’-agcacagtttgggagagtgg-3’ (forward) and 
5’-ccagctgccacacaatacag-3’ (reverse), Roche probe No.4; sterol regulatory 
element-binding protein (SREBP; GeneBank accession number: NM011480), 
5’-ggttttgaacgacatcgaaga-3’ (forward) and 5’-cgggaagtcactgtcttggt-3’ (reverse), Roche 
probe No.78; and fatty acid synthase (FAS; GeneBank accession number: NM007988), 
5’-gctgctgttggaagtcagc-3’ (forward) and 5’-agtgttcgttcctcggagtg-3’ (reverse), Roche 
probe No.58. Delta Ct was calculated by subtraction of the crossing point cycle of the 
housekeeping gene from those of the other genes analyzed. All data for mRNA 
expression level, except for Fig. 3-1A and Fig. 3-3, are presented as a ratio relative to 
the control. 
Statistical analyses were performed with JMP 10 (SAS Institute Japan) and Excel 
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Toukei 2010 (Social Survey Research Information, Tokyo, Japan). 
 
3-3 Results 
Body weight and visceral fat 
Body weight differed little between the 45%FD and 45%FD+Lg groups throughout 
the experiments. However, the weight of the periovarian fat was significantly lower in 
group 45%FD+Lg than in group 45%FD (p < 0.05). The relative weight (% in body 
weight) of the periovarian fat of group 45%FD+Lg was nearly the same as that of group 
10%FD (Table 3-2). 
 
Gene expression in the periovarian adipose tissue and the liver 
The relative expression levels of ADRB3 in the periovarian fat decreased with the 
increase in periovarian fat weight (p < 0.01) (Fig. 3-1A). However, there were no 
differences between group 45%FD+Lg and group 45%FD (Fig. 3-1B), contrary to our 
expectations. The relative expression of TNF-α mRNA in the periovarian fat was lower 
in group 45%FD+Lg than in group 45%FD (p < 0.05) (Fig. 3-4A). The MCP-1 
expression level in the periovarian fat was significantly enhanced by feeding a high fat 
diet (45%FD). However, there was no significant difference between groups 45%FD 
and 45%FD+Lg (Fig. 3-4B). 
The relative expression of hepatic SREBP mRNA was lower in group 45%FD+Lg 
than in group 45%FD (p < 0.05). The relative expression of hepatic FAS mRNA was 
lower in group 45%FD+Lg than in group 45%FD (p < 0.05). The relative expression of 
hepatic INSR mRNA was higher in group 45%FD+Lg than in group 45%FD (p < 0.01) 
(Fig. 3-5). 
 
Glycerol release from the periovarian fat 
A portion (ca. 20 mg) of the periovarian adipose tissue released around 0.30-1.31 
umol of glycerol in 3 hours. These values are considered to represent the range of the 
basal lipolytic rate. Diet significantly affected the lipolytic rate, as shown in Fig. 3-2A 
and Fig. 3-2B.  
The relationship between the glycerol release and periovarian fat weight is also 
shown in Fig. 3-2A. Glycerol release decreased with the increase in periovarian fat 
weight (p < 0.05), but there was no difference between group 45%FD and group 
45%FD+Lg (Fig. 3-2B). A similar relationship was observed for the effect of L. gasseri 
NT, as shown in Fig. 3-1B. 
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Blood FFA, TG, and insulin 
As shown in Table 3-3, blood FFA was significantly lower in the 45%FD+Lg group 
than in the 45%FD group (p < 0.05). 
 
3-4 Discussion 
We evaluated the effects of the administration of lactic acid bacteria on  lipid 
metabolism and fat synthesis in a mouse high-fat-diet model, focusing on visceral fat.  
Lipid mobilization from the adipose tissue releases FFA and glycerol. This 
mobilization is mediated by the sympathetic nervous system; norepinephrine is the most 
potent regulator of lipid mobilization in adipocytes (Commins et al., 1999). This 
stimulation is mediated by the β3 adrenaline receptor (Susulic et al., 1995). For this 
reason, mRNA expression of ADRB3 was used to evaluate lipolysis (Ushida et al., 2011, 
Zhang et al., 2008, Rayner et al., 2001). In this context, an ex vivo test is a beneficial 
way to evaluate directly lipid mobilization because ADRB3 expression is an indirect 
indicator of fat mobilization. It was shown in this experiment that the heavier visceral 
adipose tissue had a lower expression of ADRB3. Therefore, the negative correlation 
between adipose tissue weight and ADRB3 expression level suggests the involvement of 
ADRB3 in the development of obesity, as indicated by earlier studies (Cao et al., 2011). 
Declines in adrenergic receptor expression may result in lower lipid mobilization (p < 
0.05) (Fig. 3-3), which leads to the development of obesity. However, this was not the 
case when we compared groups 45%FD+Lg and 45%FD. The periovarian fat weight in 
the former group was significantly lower than that in the 45%FD group without a 
significant difference in ADRB3 expression and glycerol release. This suggests that the 
anti-obesity effects of L. gasseri NT may have other mechanisms. Lipid mobilization is 
induced by excited sympathetic nerves. Indeed, stimulation of autonomic nerve systems 
by intraduodenal administration of lactic acid bacteria was observed in the study of 
Nagai et al. (Nagai et al., 2009), in which decline of renal sympathetic nerve activity 
was suggested. 
Obesity leads to infiltration of macrophages in adipose tissues with a concomitant 
increase in pro-inflammatory cytokines, such as TNF-α (Uysal et al., 1997). Since the 
level of TNF-α in adipose tissue correlates with the degree of adiposity and insulin 
resistance (Uysal et al., 1997), TNF-α, therefore, is a key molecule that exacerbates the 
lifestyle-related diseases caused by obesity. In this experiment, a high-fat diet did not 
enhance TNF-α expression significantly. Therefore, it was suggested that the level of 
inflammation in adipose tissue in the 45%FD group was not severe. Administration of L. 
gasseri NT significantly decreased TNF-α expression in the periovarian fat tissue in this 
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experiment. It is known that L. rhamnosus GG decreased TNF-α production in a murine 
macrophage cell line, RAW 264.7 (Pena et al., 2003). Inactivation of macrophages by 
lactobacilli may be a common phenomenon for probiotic lactobacilli (Inoue et al., 2007). 
For example, L. casei Shirota suppressed the production of TNF-α by macrophages 
(Yasuda et al., 2008). 
If macrophages are the main target of lactic acid bacteria to reduce TNF-α expression 
in adipose tissue, their infiltration may be affected by L. gasseri NT. Monocyte 
chemoattractant protein 1 (MCP-1) and its receptor, CCR2, play pivotal roles in the 
development of inflammatory responses. Macrophage infiltration in adipose tissue 
induced by feeding on a high-fat diet for normal wild-type mice was not observed in 
CCR2-KO mice, and there was a significant reduction in TNF-α mRNA expression 
(Weisberg et al., 2003, Weisberg et al., 2006, Kanda et al., 2006). Accordingly, it is 
reasonable to conclude that most TNF-α in adipose tissues is induced by infiltrated 
macrophages. The increase in MCP-1 expression in adipose tissue in the 45%FD group 
suggests the pro-inflammatory status of these mice. L. gasseri NT did not significantly 
alter the expression of MCP-1. Together with the reduction in TNF-α expression in the 
adipose tissue, it is suggested that L. gasseri NT has at least a preventive effect against 
inflammation induced by fat accumulation (Fig. 3-4). 
The intestine is an important immune organ, and the intestinal microbiota plays a 
crucial role in the development of local and systemic immunity. Stimulation of mucosal 
immune tissue by probiotic lactobacilli, indeed, inactivates macrophages (Inoue et al., 
2007). 
Hyperinsulinemia induces SREBP-1c expression, leading to the transcriptional 
activation of all lipogenic genes in the liver (Shimomura et al., 1999). SREBP has also 
been known to play a critical role in the development of beta-cell dysfunction in the 
pancreas caused by elevated FFA (Wang et al., 2003). In this study, the mRNA 
expression levels of SREBP and FAS were significantly lower in group 45%FD+Lg than 
in group 45%FD (Fig. 3-5). Blood serum FFA was significantly lower in group 
45%FD+Lg than in group 45%FD (Table 3-3). These results indicate that suppression of 
SREBP and FAS in the liver leads to a decrease in fatty acid synthesis and FFA. In a 
previous study, lactic acid bacteria reduced hepatic lipogenesis and particularly reduced 
in the expression of SREBP and FAS (Kitawaki et al., 2009). Administration of lactic 
acid bacteria, therefore, demonstrates anti-lipogenic effects at least in the liver. 
In this experiment, the blood insulin level was not high enough to be judged as 
demonstrating insulin resistance (Table 3-3). In addition to this, there was no significant 
difference in insulin level between groups 45%FD+Lg and 45%FD. Therefore, the 
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involvement of insulin in the effects of L. gasseri NT on lipid metabolism of mice is 
still hard to prove. 
In conclusion, oral administration of L. gasseri NT did not enhance lipid mobilization 
in adipose tissue but could reduce fat synthesis in the liver, which suggests its potential 
to prevent the development of obesity and obesity-related disorders. It is not clear in 
which pathways the stimulatory signal caused by orally administered freeze-dried L. 
gasseri NT was transmitted to the effective sites in the liver and the adipose tissue. 
Further studies are required to clarify this point. 
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Fig. 3-1. ADRB3 mRNA expression of periovarian fat. A, Relation between the delta Ct 
values of ADRB3 of periovarian fat and periovarian fat weight. y=4.87x-0.70 (r=0.71) (y, 
delta Ct values of ADRB3 of periovarian fat; x, periovarian fat weight; r, correlation 
coefficient) was obtained. Delta Ct was calculated by subtraction of the crossing point 
cycle of the β-actin gene from the ADRB3 gene. The broken lines represent 95% 
confidence lines. A significant positive correlation (p < 0.01) is shown between the 
Delta Ct values of ADRB3 and periovarian fat weight. This means that negative 
correlation is shown between the expression levels of ADRB3 and periovarian fat weight. 
B, Relative expression of ADRB3 mRNA for each group. The data were assessed by 
Dunnett’s multiple comparison tests. The mean value of the 45%FD group was set to 1. 
▲, LaboMR; ■, 10%FD; ◇, 45%FD; ×, 45%FD+Lg  ** p < 0.01 
 
 
 
 
 
 
 
 
 
26 
 
Periovarian fat weight (g)
A
G
ly
ce
ro
l r
e
le
a
se
 
(m
g
/d
L/
m
g
 p
e
ri
o
va
ri
a
n
fa
t)
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
LaboMR 10%FD 45%FD 45%FD+Lg
G
ly
ce
ro
l r
el
ea
se
 (
m
g
/d
L/
m
g)
**
B
G
ly
ce
ro
l r
el
ea
se
 
(m
g
/d
L/
m
g 
p
er
io
va
ri
an
fa
t)
 
Bioscience of Microbiota, Food and Health. 2013. 32: 51-58. 
 
Fig. 3-2. Glycerol release from periovarian fat. A, Relation between glycerol release 
from periovarian fat and periovarian fat weight. Log(y)=-0.22+0.12/x (y, glycerol 
release; x, periovarian fat weight) was obtained. A negative correlation (p < 0.05) is 
shown between the glycerol release and periovarian fat weight. B, Glycerol release from 
periovarian fat in each group. The data were assessed by Dunnett’s multiple comparison 
tests. The mean value of the 45%FD group was set to 1. 
▲, LaboMR; ■, 10%FD; ◇, 45%FD; ×, 45%FD+Lg  ** p < 0.01 
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Fig. 3-3. Relation between glycerol release from periovarian fat and the delta Ct values 
of ADRB3 of periovarian fat. y=-0.10x-1.37 (r=0.41) (y, glycerol release from 
periovarian fat; x, delta Ct values of ADRB3 of periovarian fat; r, correlation coefficient) 
was obtained. Delta Ct was calculated by subtraction of the crossing point cycle of the 
β-actin gene from that of the ADRB3 gene. A significant negative correlation (p < 0.05) 
is shown between glycerol release from periovarian fat and the delta Ct values of 
ADRB3 of periovarian fat. This means that positive correlation is shown between 
between glycerol release from periovarian fat and the expression levels of ADRB3. 
▲, LaboMR; ■, 10%FD; ◇, 45%FD; ×, 45%FD+Lg 
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Fig. 3-4. Relative expression of proinflammatory marker gene in periovarian fat. A, 
Relative expression of TNF-α mRNA in periovarian fat. The data were assessed by 
Dunnett’s multiple comparison tests. The mean value of the 45%FD group was set to 1. 
B, Relative expression of MCP-1 mRNA in periovarian fat. The data were assessed by 
Dunnett’s multiple comparison tests. The mean value of the 45%FD group was set to 1. 
**p < 0.01; *p < 0.05 
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Fig. 3-5. Relative expression of insulin receptor (INSR), sterol regulatory 
element-binding protein (SREBP) and fatty acid synthase (FAS) mRNA in the liver. 
Differences were evaluated using the Student’s t-test. 
□, 45%FD; ■, 45%FD+Lg **p < 0.01; *p < 0.05 
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Table 3-1. The composition of each diet 
Ingredient Labo MR Stock D12450B D12451 
Protein 18.80 % 19.20 % 23.70 % 
Carbohydrate 54.70 % 67.30 % 41.40 % 
Fat 3.90 % 4.30 % 23.60 % 
Calories 2.31 kcal/g 3.87 kcal/g 4.73 kcal/g 
Calories from fat 0.351 kcal/g 0.385 kcal/g 2.12 kcal/g 
Bioscience of Microbiota, Food and Health. 2013. 32: 51-58. 
 
 
Table 3-2. Effects of L. gasseri NT on body weight and periovarian fat weight 
  LaboMR 10%FD 45%FD 45%FD+Lg 
Body weight (g) 24.2 ± 1.19
**
 24.9 ± 1.77
**
 29.1 ± 2.06 28.7 ± 1.86 
Periovarian fat (g) 0.189 ± 0.061
**
 0.487 ± 0.204
**
 0.837 ± 0.294 0.585 ± 0.175
*
 
Periovarian fat (%) 0.775 ± 0.217
**
 1.921 ± 0.719
*
 2.832 ± 0.881 2.030 ± 0.559
*
 
Bioscience of Microbiota, Food and Health. 2013. 32: 51-58. 
 
Each value is the mean±SD. The data were assessed for statistical significance 
compared with the 45%FD group by Dunnett’s multiple comparison tests. A significant 
difference in periovarian fat between the 45%FD group and 45%FD+Lg group was 
observed (p < 0.05). **p < 0.01; *p < 0.05 
 
 
Table 3-3. Effects of L. gasseri NT on serum lipid and insulin 
  45%FD 45%FD+Lg 
TG (mg/dL) 108.8 ± 41.0 91.4 ± 6.3 
FFA (mEq/L) 1.103 ± 0.315 0.835 ± 0.121* 
Insulin (pg/mL) 3800 ± 1968 2773 ± 841 
Bioscience of Microbiota, Food and Health. 2013. 32: 51-58. 
 
Each value is the mean±SD. Differences were evaluated using the Student's t-test. A 
significant difference in FFA between the 45%FD group and 45%FD+Lg group was 
observed (p < 0.05). *p < 0.05 
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Chapter 4 
Lactobacillus gasseri NT decreased visceral fat through enhancement of lipid excretion 
in feces of KK-A
y
 mice 
 
4-1 Introduction 
There are as many as 10
12 
CFU bacteria in 1 g of digesta in the human intestine. They 
constitute a complex microbial community that interacts with host intestinal tissues and 
have roles not only in nutrition, but also in immunological defense against harmful 
agents. Thus, the intestinal microbial community contributes to nutritional efficiency 
and the maintenance of host health (Guarner et al., 2003). In addition to host defense, 
intestinal tissues secrete several peptide hormones that influence the movement of the 
digestive tract as well as the appetite of the host. The intestinal microbial community 
can attenuate host nutrition by modification of hormone secretion (Cani et al., 2009). 
The connection between gut microbiota and the energy homeostasis of the host is 
increasingly recognized. For example, dietary modulation of gut microbiota to increase 
the bifidobacterial population significantly reduced endotoxemia and improved glucose 
tolerance (Cani et al., 2007). This modulation also alleviates inflammation in mice fed a 
high fat diet (Cani et al., 2007). In addition to glucose metabolism, some preliminary 
studies have indicated the importance of gut microbiota in the lipid metabolism of the 
host (Cani et al., 2009). In this context, prebiotics and probiotics, which are recognized 
as intestinal flora modifiers, attract attention from those working on weight control and 
obesity prevention. In former chapter, it was confirmed that administration of L. gasseri 
NT reduced periovarian fat and serum-free fatty acid (FFA) in BALB/c mice fed a 
high-fat diet. These effects were induced by repression of fat synthesis (Yonejima et al., 
2013), but the mechanisms by which probiotics affect lipid metabolism must be 
evaluated, because BALB/c mice do not consume an excessively high-fat diet, which 
means that they are not good models for obesity due to excessive food consumption. 
Accordingly, next study was conducted using KK-A
y
 mice, a model for diabetes 
characterized by hyperphagia, hyperglycemia, hyperinsulinemia, and insulin resistance 
(Moussa et al., 1999). 
In this chapter, the effects of a probiotic, L. gasseri NT, on lipid digestion and 
metabolism in KK-A
y
 mice was evaluated by a pair-feeding approach. The reason for  
pair feeding was to eliminate the effect of L. gasseri NT on food consumption.  
 
4-2 Materials and Methods 
The experiments were approved by the Animal Experiment Committee of Kyoto 
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Prefectural University. Chemicals were purchased from Nacalai Tesque (Kyoto, Japan) 
unless otherwise stated. Four-week-old male KK-A
y
 mice were purchased from CLEA 
Japan (Tokyo, Japan). They were kept in individual cages in a room kept at 25 ± 1°C 
under a 12-h light and dark cycle. They were divided into the following groups: HFD 
(eight mice fed a 45kcal%Fat diet, D12451, Research Diets, New Brunswick, NJ, USA, 
4.73 kcal/g) and HFD+Lg (eight mice fed D12451 supplemented with freeze-dried L. 
gasseri NT at 10
9
 CFU/g, 4.73 kcal/g). The energy intake of the mice was adjusted by 
pair feeding for 5 weeks. Thus the food intake levels of the groups were nearly the same. 
Average daily food intakes were 4.79 ± 0.40 g and 4.73 ± 0.28 g, and total calorie 
intakes were 725 ± 60 kcal and 716 ± 42 kcal for the HFD and HFD+Lg groups 
respectively. The levels were slightly lower than consumption in ad libitum feeding 
(about 5 g for KK-A
y
 mice at 40 g of body weight). Body weight was measured daily. At 
the end of the experiment, the mice were dissected under general anesthesia to remove 
periovarian fat and the liver. The periovarian fat was considered to represent visceral 
adipose tissue. After removal, a portion (about 500 mg) of the periovarian fat was 
collected in RNAlater
®
 solution (Sigma, Tokyo, Japan) for mRNA analysis. A portion 
(about 500 mg) of the liver was also collected in RNAlater
®
 solution for mRNA 
analysis. These subsamples were stored at -30ºC after overnight fixation in RNAlater
®
. 
The other portion (about 500 mg) of the liver was freeze-dried for lipid extraction. The 
entire intestine was removed, and the distal portion of the ileum, 1 cm from the 
ileocecal valve, was collected in RNAlater
®
 solution for mRNA analysis. At the same 
time, the entire ileal digesta were collected and immediately stored at -30ºC. Blood 
samples were collected from the inferior vena cava. Sera were stored at -30ºC until 
analysis. Fecal samples were collected at the time of dissection and stored at -30ºC until 
biochemical analysis. Portions of the feces were further freeze-dried for lipid extraction. 
The serum levels of triglycerides (TG), total cholesterol (T-cho), free fatty acid (FFA), 
and glucose were determined by TG E-test (Wako), Cholesterol E-test Wako (Wako), 
NEFA C-test (Wako), and Glutest Every
®
 (Sanwa Kagaku Kenkyusyo, Aichi, Japan) 
respectively. Total RNA was extracted from the periovarian adipose tissue and the liver, 
and cDNA was synthesized as reported in a previous study (Yoshikawa et al., 2009). 
The expression levels of the target genes were determined by the real-time PCR 
approach using by the use of LightCycler
®
 480 (Roche Applied Science, Tokyo, Japan). 
PCR was performed with a thermal cycle program with initial denaturation at 95°C for 
5 min, followed by 50 cycles of 95°C for 10 s and 60°C for 20 s. In this analysis, the 
β-actin gene was used as housekeeping gene. The target genes with their GenBank 
accession numbers were as follows: β-actin (GenBank accession number: NM007393), 
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Cholesterol 7α-hydroxylase (CYP7) (GenBank accession number: NM007824.2), 
Monocyte chemo-attractant protein 1 (MCP-1, CCL2) (GenBank accession number: 
NM011333), Fatty acid transport protein 2 (FATP2, Slc27a2) (GenBank accession 
number: NM011978.2), and Fatty acid transport protein 4 (FATP4, Slc27a4) (GenBank 
accession number: NM011989.4). The primers and probes used in this study were 
designed by means of software (https://www.roche-applied-science.com/). Delta Ct was 
calculated by subtracting the crossing point cycle of the housekeeping gene (beta-actin) 
from those of the other genes analyzed. All data for mRNA expression are presented as 
the ratio of the level for HFD+Lg relative to that in the control, HFD. Extraction of total 
lipids from the freeze-dried liver and feces was carried out by the ordinary method 
(Forch et al., 1956). Briefly, portions of the liver (about 30 mg) or feces (about 10 mg) 
were extracted by chloroform-methanol solution. The total lipids of the extracts were 
measured as constant weight after evaporation of the solvent. The TG concentration in 
the extract resolved by 2-propanol (1 mL) was further determined by TG E-test. 
Determination of the bile acid concentrations in the feces and digesta was carried out as 
reported by Higaki et al. (Higaki et al., 2006). A portion of the feces (about 10 mg) or 
the ileal digesta (about 10 mg) was extracted with 90% ethanol, and extracts were 
further subjected to the Total Bile Acid Test (Wako, Osaka, Japan). Determination of the 
lipase activity of the ileal digesta was carried out by means of Lipase Kit S (DS Pharma 
Biomedical, Osaka, Japan). Digesta were diluted 40-hold with distilled water before 
analysis. Activities were expressed as values relative to that of 10 U/mL of porcine 
pancreatic lipase. Student’s t-test was done after an F-test, which confirmed 
homoscedasticity. Statistical analyses were performed with Excel Toukei 2010 (Social 
Survey Research Information, Tokyo). 
 
4-3 Results  
The body weight of mice was nearly the same for the HFD and HFD+Lg groups 
throughout the experiment, but the weight (g) and relative weight (% of body weight) of 
the periovarian (p < 0.01) fat and the liver (p < 0.05) were both significantly lower in 
the HFD+Lg group than in the HFD group (Table 4-1). In addition, total lipids and TG 
in the liver were significantly lower in the HFD+Lg group than in the HFD group (p < 
0.01) (Table 4-3). 
There was no significant difference in serum TG levels between the two groups, but 
HFD+Lg mice showed significantly lower T-cho (p < 0.01), FFA (p < 0.05), and glucose 
(p < 0.05) than the HFD mice (Table 4-2). The HFD+Lg mice showed significantly 
higher fecal TG and intestinal bile acid than the HFD mice (p < 0.05) (Table 4-3). 
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The HFD+Lg mice showed higher relative expression of CYP7 mRNA in the liver than 
the HFD mice (p < 0.05), but the HFD+Lg mice showed lower periovarian fat MCP-1 
mRNA expression and jejunal FATP2 and FATP4 mRNA than the HFD mice (p < 0.05) 
(Fig. 4-1). 
The relative lipase activity of the ileal digesta was lower in the HFD+Lg group than in 
the HFD group (p < 0.05) (Fig. 4-2). 
 
4-4 Discussion 
In this experiment, oral administration of L. gasseri NT significantly increased the 
fecal TG concentration, which suggests that lipid digestion and/or absorption was 
repressed by feeding of L. gasseri NT. Decreased lipid absorption might explain the 
reduction in visceral fat weight and blood FFA, in that ileal lipase activity decreased 
10% and mRNA expression of fatty acid transport proteins in the small intestine was 
down regulated by feeding of L. gasseri NT. Significantly lower serum cholesterol 
confirms reduced lipid digestion and/or absorption in the small intestine. 
Recently, Matsumura (Matsumura et al., 2010) reported that L. gasseri NLB367 
inhibited pancreatic lipase in vitro, though he did not describe in detail the mechanisms 
of inhibition. There are several possible mechanisms for lactobacillal inhibition of 
lipase: that L. gasseri NLB367 reacts directly with lipase to prevent lipase from binding 
with its substrate, or L. gasseri NLB367 inhibits micelle formation. Matsumura stressed 
in his report that a wide variety of lactobacilli inhibit lipase. Accordingly, it is plausible 
that its inhibitory effect on lipase is not species- or strain-specific. The latter possibility, 
inhibition of micelle formation, is more plausible as an inhibitory mechanism.    
On the other hand, the bile acid concentration of the ileal digesta increased. Indeed, the 
color of the ileal digesta changed visually, becoming redder. It is interesting to consider 
why the bile acid concentration was elevated when the lipase activity was decreased by 
feeding of L. gasseri NT. Increased hepatic expression of CYP7 mRNA might explain 
the increased bile acid concentration in the small intestinal digesta, because Cholesterol 
7α-hydroxylase, CYP7, is the enzyme that catalyzes the synthesis of bile acid from 
cholesterol. In considering the fecal bile acid concentration, which did not differ 
between the groups of animals, the size of the bile acid pool should have increased in 
the jejunum and the ileum. If micelle formation was significantly inhibited by L. gasseri 
NT under the high-fat diet, more bile acid might be secreted to support fat digestion and 
absorption. Inhibition of micelle formation occurres when bile acid is absorbed by 
hydrophobic materials such as soy peptide (Nagaoka et al., 2010). A range of lactic acid 
bacteria absorb and retain bile acids within the cell (Yokota et al., 2000), (Kurdi et al., 
35 
2000), which may inhibit the micelle formation. Moreover, the solubility of bile acid 
can be affected indirectly by L. gasseri NT, because bile acids become insoluble when 
the intestinal pH is lower than 6.5. If the pH condition in the intestine becomes low due 
to acids produced by lactic acid bacteria, bile acid becomes inactive as to forming 
micelles (Narusawa et al., 1998). 
Lowered lipase activity might also explain the increase in bile acid pool in the small 
intestine. This is consistent with the finding that the administration of chitosan, which 
inhibits pancreatic lipase activity, induced bile acid excretion in a rat model (Gallaher et 
al., 2000). 
A negative correlation has been found between the LDL-cholesterol concentration in 
blood and bile acids in the intestine (Furuya et al., 2006). A reduction in bile acid 
biosynthesis might increase hepatic cholesterol and oxysterol levels, which should 
influence the function of the lipogenic SREBP-1c by attenuating processing and 
activation of it (Watanabe et al., 2013). SREBPs, family members of membrane-bound 
transcription factors, regulate lipid homeostasis by controlling enzymes such as fatty 
acid synthase (FAS). Indeed, overexpression of nSREBP-1c in the liver produces a 
triglyceride-enriched fatty liver (Horton et al., 2002). This might decrease hepatic TG 
production. 
At the transcriptional level, bile acids, which are endogenous ligands of the hepatic 
farnesoid X receptor (FXR), activate the transcription of several hepatic genes that can 
modulate TG levels, such as the atypical nuclear receptor small heterodimer partner 
(SHP) (Goodwin et al., 2000) and PPARα (Torra et al., 2003). PPAR-α is a nuclear 
receptor that regulates hepatic lipid metabolism by up regulating carnitine palmitoyl 
transferase 1 (CPT-1), which oxidizes fatty acids (Brandt et al., 1998). 
Since bile acids have many regulatory functions in lipid metabolism, the effect of L. 
gasseri NT on lipid metabolism may be elicited by induction of bile acid secretion. This 
aspect should be examined in further studies. The serum bile acid could not be 
determined in this experiment due to the blood sample’s limited quantity. Moreover, not 
all feces were collected in this experiment. The limited fecal sample also limited the 
discussion of the bile acid balance. Additional study that focuses on bile acid 
metabolism should be considered.  
In conclusion, oral administration of L. gasseri NT decreased visceral fat weight 
through inhibition of lipase and, plausibly, reduction of bile acid activity in the intestine.  
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Fig. 4-1. Relative expression of CYP7 mRNA in the liver, MCP-1 mRNA in the 
periovarian fat, and FATP2 and FATP4 in the intestine. Values are mean ± SD. 
Differences were evaluated by Student’s t-test. 
, HFD; , HFD+Lg * p < 0.05 
Modified from Yonejima et al., (2013) 
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Fig. 4-2. Relative lipase activity of intestinal digesta to porcine pancreatic lipase (10 
U/mL). Intestinal digesta was diluted with water by 40-hold. Values are mean ± SD. 
Differences were evaluated by Student’s t-test. 
, HFD; , HFD+Lg * p < 0.05 
Modified from Yonejima et al., (2013) 
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Table 4-1. Effects of L. gasseri NT on body weight, periovarian fat weight and liver 
weight 
  HFD HFD+Lg 
Body weight (g) 44.6 ± 2.3 43.0 ± 2.3 
Periovarian fat weight (g) 3.26 ± 0.48 2.60 ± 0.36** 
Periovarian fat weight (g/100g body weight) 7.28 ± 0.75 6.03 ± 0.69** 
Liver weight (g) 2.50 ± 0.26 2.14 ± 0.23* 
Liver weight (g/100g body weight) 5.62 ± 0.50 4.98 ± 0.53* 
HFD, group fed high-fat diet (45kcal%Fat diet); HFD+Lg, group fed high-fat diet 
(45kcal%Fat diet) supplemented with L. gasseri NT. Values are mean ± SD. 
Differences were evaluated by Student’s t-test. **p < 0.01, *p < 0.05 
Modified from Yonejima et al., (2013) 
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Table 4-2. Effects of L. gasseri NT on serum lipids, blood glucose level 
  HFD HFD+Lg 
Serum TG (mg/dL) 229 ± 141 115 ± 76 
Serum T-cho (mg/dL) 163 ± 22 130 ± 20** 
Serum FFA (mEq/L) 1.77 ± 0.83 0.86 ± 0.20* 
Blood glucose level (mg/dL) 526 ± 88 397 ± 103* 
HFD, group fed high-fat diet (45kcal%Fat diet); HFD+Lg, group fed high-fat diet 
(45kcal%Fat diet) supplemented with L. gasseri NT. TG, triglyceride; T-cho, total 
cholesterol; FFA, free fatty acid. Values are mean ± SD. Differences were evaluated 
using the Student’s t-test. **p < 0.01, *p < 0.05 
Modified from Yonejima et al., (2013) 
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Table 4-3. Effects of L. gasseri NT on lipids and TG in the liver, TG and bile acid in the 
feces, and bile acid in digesta 
  HFD HFD+Lg 
Liver 
  
Total lipids (g/100g freeze-dried hepatic tissue) 21.0 ± 6.0 14.6 ± 3.5* 
Total lipids (mg liver) 212 ± 72 111 ± 17** 
TG (g/100g freeze-dried hepatic tissue) 11.7 ± 3.3 5.4 ± 1.6* 
TG (mg liver) 119 ± 41 42 ± 13** 
Feces 
  
TG (g/100g freeze-dried feces) 18.4 ± 5.0 26.3 ± 11.0* 
Bile acid concentration (μmol/g wet feces) 2.26 ± 0.68 1.82 ± 0.46 
Small intestinal digesta 
  
Bile acid (μmol/g wet digesta) 19.8 ± 5.4 25.8 ± 7.0* 
Total bile acid (μmol) 2489 ± 1318 2971 ± 1442 
Weight (mg) 125 ± 58 128 ± 76 
Weight (mg dry water) 31.1 ± 14.7 32.1 ± 19.4 
HFD, group fed high-fat diet (45kcal%Fat diet); HFD+Lg, group fed high-fat diet 
(45kcal%Fat diet) supplemented with L. gasseri NT. TG, triglyceride. Values are mean 
± SD. Differences were evaluated using the Student’s t-test. **p < 0.01, *p < 0.05 
Modified from Yonejima et al., (2013) 
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Chapter 5 
General discussion and conclusion 
 
5-1 General discussion 
In this study, I have determined the effect of probiotics on indigenous intestinal 
microbiota and their effects on lipid metabolism in both normal and obese models under 
high-fat-diet feeding. 
Probiotics used in chapter 2 contained either B. natto NT or L. acidophilus NT. 
It was confirmed that administration of the tablet for 10 days increased bifidobacterial 
population together with their symbiotic bacteria, such as Acidaminococcus spp., 
Megamonas spp., and an unknown butyrate-producing bacterium. 
The increase in bifidobacteria by probiotics was the major observation throughout the 
study. As indicated by Ohashi et al. (2001), probiotics may have the potential to modify 
indigenous intestinal microbiota in general, even though they do not colonize in the 
intestine. Our observation seems to provide another example to explain the effect of 
probiotics that do not colonize in the intestine. At present, the mechanisms for such 
growth promotion of indigenous bifidobacteria or other intestinal bacteria remain 
unclear. However, the probiotic strains should have grown to some extent in order to 
show such growth promotion for the indigenous bacteria. It is noteworthy that other 
bacteria affected by probiotics were the acid-utilizing bacteria. Probiotic strains were 
lactic acid bacteria, which produce lactate and acetate (or only lactate if they are homo 
fermenters). These acids can be converted into butyric acid by butyrate producers, such 
as Acidaminococcus and Megasphaera elsdenii, or other lactate-utilizing butyrate 
producers (Tsukahara et al., 2002; Duncan et al., 2007). It is plausible that growth 
promotion of these acid-utilizing bacteria may help further the growth of indigenous 
lactate producer, such as bifidobacteria or lactobacilli. Accordingly, the indirect effect 
of probiotics seems to be quite visible: a stimulation of the indigenous bifidobacteria or 
lactobacilli through the growth of indigenous acid-utilizing bacteria.  
Regarding enteric disorders, bifidobacteria can protect from enteropathogenic infection 
through the production of acetate (Fukuda et al., 2011). Bifidobacteria was also 
effective in reducing constipation (Yaeshima et al., 1997; Yang et al., 2008). Probiotics 
composed of bifidobacteria were also effective to prevent allergies (Xiao et al., 2007; 
Taniuchi et al., 2005) and obesity (Kondo et al., 2010; Yin et al., 2010). These 
beneficial health effects must be caused by the increase in indigenous bifidobacteria 
unless the probiotic strain grows well in the intestine in the case of B. animalis 
(Ishizuka et al., 2012). 
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In this study, the effects of the probiotic strain on obesity were focused. As noted 
above, many studies have been conducted to demonstrate the positive effect of 
probiotics on obesity (Kitawaki et al., 2009; Kadooka et al., 2010). Since obesity causes 
diabetes, hyperlipidemia, hypertension, and arteriosclerosis, effective remedies for 
obesity are still needed (Norman et al., 1989).  
Studies conducted in this decade have revealed that obesity is caused by a coordinated 
mechanism involving several organs and tissues (Das et al., 2010). Possible target 
organs and/or tissues for the treatment of obesity are presented in Fig. 5-1. 
In adipose tissue, the adrenergic receptor (ADRB) plays an important role in 
metabolism, which mediates the catecholamine-induced lipolysis. Thus, the adrenergic 
system plays a key role in regulating energy balance through thermogenesis and lipid 
metabolism (Deram et al., 2009). In addition, adipose tissue secretes many biologically 
active substances: adipocytokines such as leptin, adiponectin, tumor necrosis factor α 
(TNF-α), and monocyte chemoattractant protein 1 (MCP-1). TNF-α and MCP-1 are 
up-regulated, but adiponectin is down-regulated in obese adipose tissue. It is widely 
accepted that inflammatory cytokines accumulated within the adipose tissue critically 
contribute to the development of many aspects of the metabolic syndrome result ing in 
diabetes and atherosclerosis (Matsuzawa et al., 1999; Hotamisligil et al., 1993; Sartipy 
et al., 2003; Takahashi et al., 2010).  
In the liver, sterol regulatory element binding proteins (SREBPs), family members of 
membrane-bound transcription factors, regulate lipid homeostasis by controlling 
enzymes such as fatty acid synthase (FAS). Indeed, overexpression of nSREBP-1c in 
the liver produces a triglyceride-enriched fatty liver (Horton et al., 2002). On the other 
hand, the peroxisome proliferator-activated receptor α (PPAR-α) is a nuclear receptor 
that regulates liver lipid metabolism by up-regulating its target enzyme of FA oxidation, 
carnitine palmitoyl transferase 1 (CPT-1) (Brandt et al., 1998). 
Regarding mitochondria, energy combustion is controlled by peroxisome 
PPAR-α-regulated mitochondrial and peroxisomal fatty acid β-oxidation systems. 
Stimulation of mitochondrial fatty acid β-oxidation by PPAR-α activator in the liver and 
muscle contributes to reducing plasma triglycerides (Kim et al., 2012). 
Finally, in the brain, the hypothalamus has a key role in the control of both body fat 
content and glucose metabolism. The neuronal system, which regulates energy intake, 
energy expenditure, and endogenous glucose production, senses and responds to input 
from hormonal and nutrient-related signals that convey information regarding both body 
energy stores and current energy availability (Schwartz et al., 2000).   
New pathways related to lipid metabolism have been continuously discovered, and 
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these novel pathways became potential targets for drug development in the treatment of 
obesity. Probiotics can also affect these targets to prevent obesity; therefore, we have 
conducted a series of experiments using normal mice and spontaneous diabetic mice 
under high-fat-diet feeding. 
In chapter 3, we evaluated the effects of probiotic L. gasseri NT on lipid metabolism 
of the visceral adipose tissues in Balb/c mice under high-fat-diet feeding. Balb/c mice 
was chosen because this strain was normal and one of the most widely used strains. In 
this experiment, L. gasseri NT did not stimulate lipolytic activity in the visceral adipose 
tissue (Figs. 3-1B and 3-2B). This finding was a bit unexpected because probiotics can 
enhance sympathetic stimulation (Nagai et al., 2009), which is received by ADRB3. 
Modification of intestinal microbiota may help to reduce the LPS burden, which 
down-regulates ADRB3 in adipose tissue (Ushida et al., 2011), because the ADRB3 of 
adipose tissue is down-regulated by TNF-α released by infiltrated monocytes in 
response to LPS. L. gasseri NT did not up-regulate ADRB3 in the visceral adipose 
tissues. However, L. gasseri NT decreased the mRNA expression of SREBP and its 
target gene, FAS, in the liver (Fig. 3-5). The induction of hepatic SREBP was observed 
in Hepatitis C virus (HCV) infection through TNF-α activation (Li et al., 2013); 
accordingly, L. gasseri NT reduced the hepatic LPS burden. As shown by the previous 
study, an increase in bifidobacteria cured the endotoxemia (Cani et al., 2007). L. gasseri 
NT probably decreased the portal LPS burden, which may have reduced TNF-α 
response. The reduction in the portal LPS burden may not be enough to reduce 
inflammatory responses in tissues or peripheral organs other than the liver. 
Measurement for blood LPS is not an easy task due to the low level of concentration. In 
recent experiment, however, the daily supply of portal LPS was significantly decreased 
by the feeding of gum arabic to mice (Iida et al., personal communication).   
In this study, I have evaluated the effect of a probiotic, L. gasseri NT, on lipid 
digestion and metabolism in KK-Ay mice with a pair-feeding approach. In the former 
study, BALB/c mice did not consume a high-fat diet excessively, which means that this 
strain is not a good model for the obesity induced by excessive food intake. Accordingly, 
a study using KK-Ay mice was conducted, which are the model for diabetes 
characterized by excessive food intake. 
Oral administration of L. gasseri NT decreased the visceral fat and total lipids in the 
liver (Tables 4-1 and 4-3). The reduction was caused by suppression of lipid absorption 
through the inhibition of intestinal lipase and, plausibly, by a reduction in bile acid 
activity in the intestine (Fig. 5-2).  
Probiotics can interact with bile acids to reduce the bioavailability of bile acids 
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(Al-Salami et al., 2012). Probiotics absorb or even hydrolyze bile acids. L. gasseri NT 
can bind cholesterol onto the cell wall (Usman and Hosono, 1999). Bile salt hydrolases 
(BSHs, EC. 3.5.1.24) are another determinant originating from probiotics in bile acid 
metabolism. BSHs are detected in a range of probiotic strains (Tanaka et al., 1999). The 
presently used L. gasseri NT also has bile salt hydrolases. The literature supports our 
expectation regarding interaction between L. gasseri NT and bile acids. 
The mechanism of interaction between bile acids and intestinal microbiota is still 
under debate (Pavlovic et al., 2012). Further studies are required to define the effect of 
probiotics on bile acid-related lipid metabolism. 
 
5-2 Conclusion 
 The present study demonstrated the beneficial function of probiotics against obesity. 
The first study demonstrated that oral administration of a tablet containing L. 
acidophilus, B. natto, and stomachic herbs can affect the human intestinal microbiota by 
increasing indigenous bifidobacteria. The second and the third studies demonstrated that 
administration of L. gasseri NT did not enhance lipid mobilization but reduced fat 
synthesis and lipid absorption. L. gasseri NT retain bile acids within the cell, which may 
inhibit the micelle formation and induce the secretion of additional bile acids. Bile acid 
is a key factor for prevention of fat accumulation. These results demonstrate the 
potential of probiotics to prevent development of obesity and obesity-related disorders. 
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Fig. 5-1. Possible target organs/tissues for obesity treatment and possible effects of L. 
gasseri NT. The solid arrows represent the pathway induced by high-fat-diet feeding. 
The broken arrows represent the pathways induced by administration of L. gasseri NT. 
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Fig. 5-2. Possible mechanism of anti-obesity effects by L. gasseri NT.  
, Bile acid; , Lipid; , Lipase;    , Inhibition of lipase; ○+ , Up-regulation 
by L. gasseri NT; ○- , Down-regulation by L. gasseri NT. 
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Summary 
 
Chapter 1 
 The intestinal microbial community contributes to the nutritional efficiency and 
maintenance of host health. Probiotic bacteria, namely lactobacilli and bifidobacteria, 
are now well recognized for their health promoting effects. Several diseases are related 
in intestinal microbiata. For example, obesity are associated with low-grade 
inflammation and an altered composition of the gut microbiota, a bacterial compound 
might act as a triggering factor in the development of obesity, diabetes mellitus and 
inflammation induced by a high-fat diet. The aims of this study were to investigate the 
effect of tablet containing both probiotic and medicinal herbs on the fecal microbiota in 
human, and to evaluated the effect of a probiotic, L. gasseri NT, on lipid metabolism in  
normal and obese mice model. 
 
Chapter 2 
We evaluated the effects of a tablet containing Bacillus natto and Lactobacillus 
acidophilus as probiotics supplemented with three stomachic herbs on human fecal 
microbiota. Six healthy subjects ingested 3 tablets, 3 times a day after meals for 10 days. 
Fecal samples were collected before and after the administration period, and 1 week 
post administration. As shown by the TGGE images, the density of the bands identified 
with Bifidobacterium increased in four cases. This increase was confirmed by real-time 
PCR. It was observed that the densities of the bands identified with Haemophilus 
decreased, Ruminococcus decreased, Clostridium colinum decreased, Acidaminococcus 
increased and Megamonas increased individually. 
 
Chapter 3 
Visceral fat accumulation is a major risk factor for the development of obesity-related 
diseases, including diabetes, hyperlipidemia, hypertension, and arteriosclerosis. 
Stimulation of lipolytic activity in adipose tissue or inhibition of fat synthesis is one 
way to prevent these serious diseases.  Lactic acid bacteria have an anti-obesity effect, 
but the mechanisms are unclear. Therefore, we evaluated the effect of the administration 
of lactic acid bacteria (Lactobacillus gasseri NT) on lipid metabolism and fat synthesis 
in a mouse high-fat-diet model, focusing on visceral fat. Balb/c mice were fed a 45 
kcal% fat diet for 13 weeks with and without a freeze-dried preparation of L. gasseri NT 
(10
9
 CFU/g). An ex vivo glycerol assay with periovarian fat revealed that L. gasseri NT 
did not stimulate lipolytic activity. However, L. gasseri NT decreased the mRNA 
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expression of sterol regulatory element-binding protein (SREBP) and its target gene 
fatty acid synthase (FAS) in the liver and decreased free fatty acid (FFA) in the blood. In 
conclusion, these findings indicated that administration of L. gasseri NT did not 
enhance lipid mobilization but can reduce fat synthesis, suggesting its potential for 
improving obesity-related diseases. 
 
Chapter 4 
Dietary supplementation with Lactobacillus gasseri NT significantly decreased 
visceral fat weight and triglyceride (TG) in the liver in KK-Ay mice on a high-fat diet, 
but increased fecal TG. A decrease in lipase activity and down regulation of fatty acid 
transport proteins in the small intestine was involved in fat accumulation by L. gasseri 
NT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
Acknowledgements 
 
 I would like to express my sincere gratitude to all colleagues, family, friends and 
relatives, who have supported me until now. Without their participation, it would have 
been impossible for me to complete this study. 
 First of all, I would like to express my sincerest gratitude to Professor Kazunari Ushida, 
Laboratory of Animal Science, Kyoto Prefectural University, for his valuable 
suggestion, discussion throughout this work and critical reading of this manuscript. I 
learned from him what science is, and what a scientist is. 
 I’m very grateful to Dr. Ryo Inoue, Lecturer in Laboratory of Animal Science, Kyoto 
Prefectural University, for sharing his knowledge of molecular Microbiology and his 
technical supports. 
 This study was supported by Nitto Pharmaceutical industries, Ltd. I’m grateful to the 
president Tetsuro Kitao and the past and present members of research and development  
department. 
 I would like to give special thanks to the past and present members of Laboratory of 
Animal Science for their constant support and unforgettable friendship. 
 Needless to say, I’m very grateful to my family, father, mother, brother for their warm 
encouragement and support. 
 Finally, I wish to give my greatest thanks to my wife Yoko Yonejima and son Takuma 
Yonejima for their hearty encouragement and support. 
